Investigational new drugs for brain cancer.

ABSTRACT:

Introduction

Despite substantial improvements in standards of care, the most common aggressive pediatric and adult high-grade gliomas (HGG) carry uniformly fatal diagnoses due to unique treatment limitations, high recurrence rates and the absence of effective treatments following recurrence. Recent advancements in our understanding of the pathophysiology, genetics and epigenetics as well as mechanisms of immune surveillance during gliomagenesis have created new knowledge to design more effective and target-directed therapies to improve patient outcomes.

Areas covered

In this review, the authors discuss the critical genetic, epigenetic and immunologic aberrations found in gliomas that appear rational and promising for therapeutic developments in the presence and future. The c

SUBMITTER: Staedtke V 

PROVIDER: S-EPMC5674816 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature